Size: px
Start display at page:

Download ""

Transcription

1 70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT

2 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 71 ) * * * * Meropenem (MEPM) (MIC) 1. MEPM Haemophilus influenzae Pseudomonas aeruginosa MEPM MIC 90 imipenem (IPM) ciprofloxacin (CPFX) MEPM methicillinresistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis 2. b - (ESBL) Escherichia coli 4 (3.1%) Klebsiella pneumoniae 2 (1.9%) MEPM MEPM 7

3 72( 72 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. meropenem (MEPM) 1 3) ) MEPM 1987 imipenem/cilastatin (IPM/CS) 5) 1993 panipenem/betamipron (PAPM/BP) 6) MEPM biapenem (BIPM) 7) MEPM 8) PAPM, IPM dehydropeptidase-i (DHP-I) 9) MEPM IPM, PAPM 10) MEPM MEPM I Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Providencia spp., Pseudomonas aeruginosa, Burkholderia cepacia, Acinetobacter spp., Moraxella catarrhalis, Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae b- b-lactamase producing ampicillin (ABPC)-susceptible H. influenzae (BLNAS), b -lactamase non-producing ABPCresistant H. influenzae (BLNAR) Methicillin (DMPPC)-susceptible Staphylococcus aureus (MSSA), DMPPC-resistant S. aureus (MRSA), DMPPC-susceptible Staphylococcus epidermidis (MSSE), DMPPC-resistant S. epidermidis (MRSE), coagulase-negative staphylococci CNS, S. epidermidis penicillin-susceptible Streptococcus pneumoniae (PSSP), penicillin-intermediate S. pneumoniae (PISP), penicillin-resistant S. pneumoniae (PRSP), Streptococcus milleri group (Streptococcus anginosus, Streptococcus constellatus, Streptococcus intermedius), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci (Streptococcus oralis, Streptococcus mitis, Streptococcus salivarius), Enterococcus faecalis, Enterococcus spp. E. faecalis Bacteroides fragilis group, Prevotella spp., Peptostreptococcus spp., Fusobacterium spp. 2. NCCLS 11) S. aureus oxacillin (MPIPC) MIC 2 m g/ ml MSSA, 4 m g/ml MRSA S. epidermidis, MPIPC MIC 0.25 m g/ml MSSE, 0.5 m g/ml MRSE S. pneumoniae, benzylpenicillin (PCG) MIC 0.06 m g/ml PSSP, m g/ml PISP, 2 m g/ml

4 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 73 ) PRSP H. influenzae b- ABPC MIC 2 m g/ml BLNAR, 1 m g/ml BLNAS 3. MIC MEPM, IPM, PAPM, BIPM, cefazolin (CEZ), cefaclor (CCL), cefotiam (CTM), cefmetazole (CMZ), cefotaxime (CTX), ceftriaxone (CTRX), ceftazidime (CAZ), cefozopran (CZOP), cefepime (CFPM), flomoxef (FMOX), MPIPC, PCG, ABPC, piperacillin (PIPC), sulbactam/ampicillin (SBT/ ABPC), sulbactam/cefoperazone (SBT/CPZ), gentamicin (GM), amikacin (AMK), arbekacin (ABK), tobramycin (TOB), aztreonam (AZT), vancomycin (VCM), teicoplanin (TEIC), ciprofloxacin (CPFX), clindamycin (CLDM), minocycline (MINO), linezolid (LZD) 4. NCCLS 11 13) N. gonorrhoeae (MIC) MIC Streptococcus spp., L. monocytogenes N. meningitidis (2 v/v%) cationadjusted Mueller Hinton broth (CAMHB, DIFCO) H. influenzae CAMHB (5 g/l), NAD (15 mg/l), (15 mg/l) (2 v/v%) CAMHB (5 mg/l), K 1 (1 mg/l), (5 v/v%) Brucella broth m g/ml CFU/well, 10 5 CFU/well Streptococcus spp., H. influenzae 35 C L. monocytogenes 35 C N. meningitidis 35 C 24 5% 35 C C N. gonorrhoeae MIC 1% defined growth supplement cysteine GC agar base (BBL) m g/ml 10 4 CFU/spot 35 C % 5. b - H. influenzae b - 6. b - (ESBL) NCCLS 11) CAZ AZT MIC 2 m g/ml ESBL ESBL PCR b -lactamase Real-time PCR Sequence Detection System 7000, Applied Biosystems, Primer 1 TEM- 14) SHV- 14) Toho- CTX- M-2 15) CTX-M-10 16) CTX-M ) 5

5 74( 74 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1. b- (ESBL) 50 m l 100 C 10 15,000 rpm 5 DNA PCR DNA 1m l, Primer 50 pmol, SYBR Green PCR Master Mix (Applied Biosystems) 25 m l 50 m l 50 C 2 94 C 10 PCR PCR Tm PCR 7. (PFGE) ISHII 18) TENOVER 19) XbaI II (33.9%) 512 (20.0%) (53.9%) 2. MIC 3 37 MIC MIC 50% MIC (MIC 50 ), 90% MIC (MIC 90 ) MIC 90 MEPM (1) 1) E. coli 3: MEPM 0.25 m g/ml MEPM CFPM CFPM MIC 16 mg/ml: NCCLS Intermediate Resistant 3 (2.3%) MEPM MIC m g/ml PAPM 2 IPM BIPM 3 Citrobacter spp. 4: MEPM 1 m g/ml MEPM CPFX CPFX (MIC 2 m g/ml) 4 (4.3%) MEPM MIC 90

6 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 75 ) m g/ml IPM, PAPM, BIPM 4 K. pneumoniae 5: MEPM 0.25 m g/ml MEPM CFPM, CPFX CFPM (MIC 16 m g/ml) 2 (1.9%) MEPM MIC m g/ml PAPM 3 IPM BIPM 4 Enterobacter spp. 6: MEPM 1 m g/ml MEPM CPFX CPFX (MIC 2 m g/ml) 10 (9.5%) MEPM MIC m g/ml IPM, PAPM BIPM 2 (MIC 8 m g/ml) PAPM 1 (1.0%),

7 76( 76 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3. E. coli 129 MIC MIC 50, MIC Citrobacter spp. 93 MIC MIC 50, MIC K. pneumoniae 105 MIC MIC 50, MIC 90

8 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 77 ) 6. Enterobacter spp. 105 MIC MIC 50, MIC S. marcescens 106 MIC MIC 50, MIC P. mirabilis 64 MIC MIC 50, MIC 90

9 78( 78 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. BIPM 2 (1.9%) S. marcescens 7: MEPM MIC 90 1 m g/ml MEPM CFPM, CPFX PAPM MIC 90 4 mg/ml MEPM MIC 90 PAPM 2 IPM BIPM 3 (MIC 8 m g/ml) MEPM 2 (1.9%), IPM 11 (10.4%), PAPM 7 (6.6%), BIPM 14 (13.2%) P. mirabilis 8: AZT MEPM, CAZ AZT (MIC 128 m g/ml) 1 (1.6%) MEPM 1 m g/ml MEPM MIC mg/ml IPM PAPM 4 BIPM 5 AZT, MEPM, CAZ CFPM CFPM (MIC 16 m g/ml) 4 (6.3%) (MIC 8 m g/ml) IPM 6 (9.4%), PAPM 4 (6.3%), BIPM 8 (12.5%) P. vulgaris 9: CPFX, MEPM MEPM 1 m g/ml MEPM MIC m g/ml BIPM 4 IPM PAPM 5 CPFX, MEPM CFPM CFPM (MIC 128 m g/ml) 3 (7.9%) (MIC 8 m g/ml) IPM 9 (23.7%), PAPM 7 (18.4%), BIPM 8 (21.1%) M. morganii 10: MEPM CFPM MEPM 1 m g/ml MEPM, CFPM CPFX CPFX (MIC 2 m g/ml) 5 (6.0%) MEPM MIC m g/ml PAPM BIPM 3 IPM 4 (MIC 8 m g/ml) IPM 9 (10.8%), PAPM 2 (2.4%) Providencia spp. 11: AZT, MEPM AZT (MIC 16 m g/ml) 2 MEPM (MIC 8 m g/ml) 1 (2.4%) MEPM 1 AMK, AZT MEPM MIC m g/ml IPM, PAPM BIPM 3 AZT, MEPM CZOP CFPM 2 (MIC 16 m g/ml) 3 (7.1%) (MIC 8 m g/ml) IPM 3 (7.1%), PAPM 1 (2.4%), BIPM 2 (4.8%) 2) P. aeruginosa 12: MEPM, TOB GM MIC 90 8 m g/ml MEPM MIC 90 IPM BIPM 1 PAPM 2 (MIC 16 mg/ml) MEPM 26 (9.3%) IPM 61 (21.8%), PAPM 99 (35.4%), BIPM 38 (13.6%) (IPM 16 m g/ml, CPFX 4 m g/ml, AMK 32 mg/ml) 10 (3.6%)

10 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 79 ) 9. P. vulgaris 38 MIC MIC 50, MIC M. morganii 83 MIC MIC 50, MIC Providencia spp. 42 MIC MIC 50, MIC 90

11 80( 80 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. B. cepacia 13: MEPM CPFX CPFX (MIC 2 m g/ml) 15 MEPM 4mg/ml (MIC 8 m g/ml) MEPM MIC 90 4 m g/ml IPM BIPM 1 PAPM 2 (MIC 8 m g/ml) IPM 5 (20.8%), PAPM 21 (87.5%), BIPM 12 (50.0%) Acinetobacter spp MINO, BIPM IPM, MEPM MEPM MIC 90 2 m g/ml BIPM MIC m g/ml IPM 1 MEPM 2 PAPM 3 MINO (MIC 8 m g/ml) 3 (3.0%) (MIC 8 m g/ml) MEPM, IPM, BIPM 2 (2.0%), PAPM 3 (3.0%) 3) M. catarrhalis 15: MEPM m g/ml MEPM MIC m g/ml PAPM 2 IPM BIPM 3 CPFX 0.25 m g/ml N. gonorrhoeae 16: CTRX, MEPM, PIPC, SBT/CPZ MEPM 0.12 m g/ml MEPM MIC m g/ml PAPM 2 IPM BIPM 3 CPFX MIC m g/ml (MIC 1 m g/ml) 48 (75.0%) N. meningitidis MIC MEPM m g/ml, IPM, BIPM m g/ml, PAPM 0.03 m g/ml MIC CTRX, CPFX m g/ml, CFPM m g/ml, CAZ, CZOP, FMOX, PCG, PIPC, SBT/CPZ 0.06 m g/ml, ABPC 0.12 m g/ml, AMK 8 mg/ml H. influenzae b- 17: CPFX, CTRX, MEPM, SBT/CPZ, CTX MEPM 1 m g/ml MEPM MIC 90 1 m g/ml IPM PAPM 1 BIPM 3 (MIC 8 m g/ml) IPM 2 (8.3%), BIPM 5 (20.8%) H. influenzae (BLNAS) 18: CTRX, CPFX, CTX, MEPM, PIPC MEPM 0.12 m g/ml MEPM MIC m g/ml PAPM 3 IPM 4 BIPM 5 BIPM (MIC 8 m g/ml) 8 (8.2%), CPFX (MIC 2 m g/ml) 1 (1.0%) H. influenzae (BLNAR) 19: CPFX, PIPC, CTRX, SBT/CPZ, MEPM MEPM 2 m g/ml MEPM MIC 90 1 mg/ml IPM PAPM 2 BIPM 4 (MIC 8 m g/ml) IPM 4 (5.9%), PAPM 3

12 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 81 ) 12. P. aeruginosa 280 MIC MIC 50, MIC B. cepacia 24 MIC MIC 50, MIC Acinetobacter spp. 99 MIC MIC 50, MIC 90

13 82( 82 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 15. M. catarrhalis 77 MIC MIC 50, MIC N. gonorrhoeae 64 MIC MIC 50, MIC H. influenzae b - 24 MIC MIC 50, MIC 90

14 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 83 ) 18. H. influenzae (BLNAS) 98 MIC MIC 50, MIC H. influenzae (BLNAR) 68 MIC MIC 50, MIC 90 (4.4%), BIPM 39 (57.4%) (2) 1) MSSA 20: MEPM m g/ml 4 MINO MIC m g/ml MINO (MIC 8m g/ml) 2 (2.5%) MRSA 21: MRSA VCM, ABK, TEIC, LZD MIC m g/ml MIC m g/ml VCM (MIC 8mg/ml) MSSE 22: MEPM m g/ml 4 MPIPC, ABK MINO MIC m g/ml

15 84( 84 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 20. S. aureus (MSSA) 80 MIC MIC 50, MIC S. aureus (MRSA) 88 MIC MIC 50, MIC 90 MRSE 23: MINO, ABK, VCM, LZD MIC m g/ml MIC mg/ml MINO (MIC 8 m g/ml) 8 (7.9%) VCM (MIC 16 m g/ml) CNS S. epidermidis 24: ABK, VCM, LZD MIC m g/ml MIC 90 4

16 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 85 ) 22. S. epidermidis (MSSE) 25 MIC MIC 50, MIC S. epidermidis (MRSE) 101 MIC MIC 50, MIC 90 8 m g/ml 4 (MIC 8 m g/ml) MPIPC-resistant CNS 2) PSSP 25: MEPM m g/ml PCG 4 PCG TEIC 0.12 m g/ml PISP 26: MEPM m g/ml TEIC TEIC,

17 86( 86 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 24. CNS S. epidermidis 48 MIC MIC 50, MIC S. pneumoniae (PSSP) 75 MIC MIC 50, MIC 90 4 VCM MIC m g/ml PRSP 27: MEPM mg/ml TEIC TEIC, 4 VCM MIC m g/ml S. milleri group 28: MEPM m g/ml PCG TEIC 4 PCG TEIC ABPC MIC m g/ml S. pyogenes 29: MEPM 4 CZOP, CFPM, PCG, ABPC, PIPC, CTX CTRX 0.06 m g/ml

18 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 87 ) 26. S. pneumoniae (PISP) 42 MIC MIC 50, MIC S. pneumoniae (PRSP) 48 MIC MIC 50, MIC S. milleri group 45 MIC MIC 50, MIC 90

19 88( 88 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 29. S. pyogenes 67 MIC MIC 50, MIC S. agalactiae 79 MIC MIC 50, MIC 90 TEIC MIC m g/ml S. agalactiae 30: MEPM m g/ml 4 PCG 0.12 m g/ml Viridans group streptococci 31: MEPM 4 4 m g/ml TEIC 4 PCG, ABPC VCM MIC 90 1 mg/ml 3) E. faecalis 32: TEIC 1 m g/ml VCM, ABPC, IPM, LZD, PAPM, MEPM, BIPM PIPC MIC m g/ml VCM (MIC 16 mg/ml) MIC m g/ml

20 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 89 ) 31. Viridans group streptococci 27 MIC MIC 50, MIC E. faecalis 102 MIC MIC 50, MIC 90 Enterococcus spp. E. faecalis 33: VCM, TEIC, LZD MIC m g/ml VCM (MIC 16 m g/ml) MIC m g/ml L. monocytogenes MIC-range MEPM 0.12 m g/ml, IPM, PAPM 0.06 m g/ml, BIPM m g/ml 4 PCG, ABPC MIC-range m g/ml MIC-range CTX m g/ml, CTRX, CFPM m g/ml, CZOP, CFPM m g/ml, FMOX 8 16 m g/ml, PIPC 2 4 m g/ml, CPFX, VCM 1 mg/ml, AMK m g/ml

21 90( 90 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 33. Enterococcus spp. E. faecalis 70 MIC MIC 50, MIC B. fragilis group 63 MIC MIC 50, MIC 90 (3) B. fragilis group 34: MEPM 4 MEPM MIC 90 4 m g/ml 4 SBT/ABPC, SBT/CPZ MIC m g/ml CLDM MIC m g/ml MIC mg/ml m g/ml 2 (MIC 8 m g/ml) MEPM IPM 4 (6.3%), PAPM 7 (11.1%), BIPM 3 (4.8%) MEPM (MIC 16 m g/ml) 1 Prevotella spp. 35: MEPM 4 MEPM MIC m g/ml 2 m g/ml 4 SBT/ABPC, SBT/CPZ, FMOX, CMZ MIC 90 8 m g/ml CLDM MIC m g/ml MIC m g/ml 128 mg/ml 2

22 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 91 ) 35. Prevotella spp. 43 MIC MIC 50, MIC Peptostreptococcus spp. 35 MIC MIC 50, MIC Fusobacterium spp. 10 MIC MIC 50, MIC 90

23 92( 92 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. (MIC 8 mg/ml) IPM PAPM 2 (4.7%) Peptostreptococcus spp. 36: MEPM 4 MEPM MIC m g/ml 2 m g/ml 4 ABPC, SBT/ABPC MIC m g/ml CLDM MIC 90 2 m g/ml (MIC 128 m g/ml) 1 (2.9%) Fusobacterium spp. 37: MEPM m g/ml 4 CLDM PIPC MIC mg/ml 0.12 m g/ml 3. MIC (1) 1 4 MIC 90 MEPM MIC ESBL E. coli K. pneumoniae 1. MIC 90

24 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 93 ) K. pneumoniae 2 (1.9%), E. coli 4 (3.1%) ESBL 38 PCR ESBL K. pneumoniae SHV- - E. coli Toho- CTX-M- b - 2 E. coli 2 (No. 2, No. 3) PFGE No. 2 No. 3 (2) P. aeruginosa 39 CPFX IPM (MIC 16 m g/ml) 61 MEPM CPFX % PAPM, BIPM 96.7%, 62.3% MEPM (MIC 16 m g/ml) 26 CPFX 50% CPFX (MIC 4 m g/ml) 54 BIPM MEPM 24.1% 25.9% IPM PAPM 44.4% 59.3% 3 MEPM MIC MEPM MIC 1 IPM 83.9% 235 /280 PAPM 96.1% 269 /280 BIPM 33.2% 93 / ESBL E. coli K. pneumoniae PFGE 39.

25 94( 94 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3. P. aeruginosa MEPM MIC 40 P. aeruginosa MEPM CPFX MEPM CPFX (3) H. influenzae 4 H. influenzae MIC b - ABPC 4 MIC BLNAR BLNAS MEPM 2 m g/ml BLNAR 5 7 MEPM MIC MEPM MIC 1 b - IPM PAPM 91.7% 22 /24 BIPM 100.0% 24 /24 BLNAS IPM PAPM 94.9% 93 /98 BIPM 96.9% 95 /98 BLNAR IPM 92.6% 63 /68 PAPM 94.1% 64 /68 BIPM 100.0% 68 /68 (4) % H. influenzae 78 S. pneumoniae 57 M. catarrhalis 38 P. aeruginosa 37 (49.6%) 10

26 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 95 ) 40. P. aeruginosa 4. H. influenzae MIC

27 96( 96 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 5. H. influenzae b-lactamase MEPM MIC 6. H. influenzae (BLNAS) MEPM MIC

28 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 97 ) 7. H. influenzae (BLNAR) MEPM MIC MEPM MIC-range MIC 50 MIC MIC 50 MIC P. aeruginosa, M. catarrhalis, BLNAS BLNAR IPM, PAPM, CZOP FMOX MIC-range, MIC 50 MIC MEPM III MEPM MEPM MIC (MIC 8 m g/ml) 660 IPM 38 PAPM 22 BIPM 34 MEPM S. marcescens 2 Providencia spp ) E. coli MEPM PBP2 PBP3

29 98( 98 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 41. MEPM MIC-range, MIC 50, MIC MEPM MIC-range, MIC 50, MIC 90

30 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 99 ) 23) ESBL E. coli 4 (3.1%) K. pneumoniae 2 (1.9%) YAGI E. coli 9794 K. pneumoniae ESBL E. coli 0.1%, K. pneumoniae 0.3% ESBL 24) ) E. coli 0.6% 1 /164 K. pneumoniae 4.0% 2 / 50 21) E. coli 5.0% 5 /100 K. pneumoniae 4.0% 2 /50 22) E. coli 0.9% 1 /110 K. pneumoniae 3.4% 3 /89 ESBL E. coli ESBL MEPM -b - Providencia spp. 1 AZT, AMK CPFX K. pneumoniae, P. vulgaris 21) P. aeruginosa MEPM MIC 90 4 MEPM OprD 25) MEPM OprD MEPM OprD MexAB-OprM 25) MEPM 21 /26 MIC m g/ml -b - OprD 2 CPFX 26) 10 (3.6%) 8 MEPM 42 Acinetobacter spp. -b - 27) (MIC 16 m g/ml) 2 (2.0%) MEPM MEPM MIC 50 MIC 90 H. influenzae BLNAR MIC BLNAS MEPM

31 100(100) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 2 m g/ml 28) MEPM MIC 4 mg/ml BLNAR IPM 11 b- 2 [8.3%], BLNAR 9 [13.2%] PAPM 12 b - 2 [8.3%], BLNAR 10 [14.7%] BIPM 75 b- 8 [33.3%], BLNAS 12 [12.2%], BLNAR 55 [80.9%] BLNAR H. influenzae H. influenzae MEPM H. influenzae PBP3A PBP3B 29) MEPM CTRX, CPFX CPFX 1 N. gonorrhoeae MEPM CPFX (MIC 1 m g/ml) (75.0%) 30) MEPM MSSA MSSE MRSA, MRSE VCM, TEIC, ABK, LZD VCM-intermediate S. aureus (VISA), VCM-resistant S. aureus (VRSA), VCM-resistant enterococci (VRE) S. pneumoniae MIC 0.5 m g/ml E. faecalis ABPC MEPM MIC 90 8 mg/ml 32 m g/ml, 16 m g/ml 31) B. fragilis group MIC 90 4 CLDM 16 m g/ml MEPM MIC 16 m g/ml 3 (4.8%) MIC 90 4 m g/ml Prevotella spp. MIC 90 8 mg/ml MEPM MIC m g/ml MEPM MIC m g/ml MEPM CLDM 3) B. fragilis group, Prevotella spp. B. fragilis group MEPM -b- 32) MEPM 7 MEPM

32 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS (101) ) Meropenem Jpn. J. Antibiotics 49: , ) 1997 Meropenem (MEPM) Jpn. J. Antibiotics 52: , ) 1999 Meropenem (MEPM) Jpn. J. Antibiotics 54: , ) pp , ) pp , ) pp , ) pp , ) Meropenem Chemotherapy 40 (Suppl. 1): , ) Meropenem Chemotherapy 40 (Suppl. 1): , ) SUNAGAWA, M.; H. MATSUMURA, Y. SUMITA, et al.: Structure features resulting in convulsive activity of carbapenem compounds: Effect of C-2 side chain. J. Antibiotics 48: , ) National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing; Twelfth informational supplement; M100 S12, ) National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard-fifth edition; M7-A5, ) National Committee for Clinical Laboratory Standards: Methods for antimicrobial susceptibility testing of anaerobic bacteria; Approved standard-fifth edition; M11-A5, ) PERILLI, M.; E. DELL AMICO, B. SEGATORE, et al.: Molecular characterization of extended-spectrum betalactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. J. Clin. Microbiol. 40: , ) YAGI, T.; H. KUROKAWA, K. SENDA, et al.: Nosocomial spread of cephem-resistant Escherichia coli strains carrying multiple Toho-1-like beta-lactamase genes. Antimicrob. Agents Chemother. 41: , ) STEWARD, C. D.; J. K. RASHEED, S. K. HUBERT, et al.: Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extendedspectrum beta-lactamase detection methods. J. Clin. Microbiol. 39: , ) MA, L.; Y. ISHII, F. Y. CHANG, et al.: CTX-M-14, a plasmid-mediated CTX-M type extended-spectrum betalactamase isolated from Escherichia coli. Antimicrob. Agents Chemother. 46: , ) ISHII, Y.; J. ALBA, S. KIMURA, et al.: Rapid pulsed-field gel electrophoresis technique for determination of genetic diversity of Serratia marcescens. J. Infect. Chemother. 8(4): , ) TENOVER, F. C.; R. D. ARBEIT, R. V. GOERING, et al.: Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33: , ) Cefoselis b Pharma Medica 20(5): , ) (4): , ) panipenem (PAPM) Jap. J. Antibiotics 55(6): , ) Meropenem Chemotherapy 40 (Suppl. 1) , ) YAGI, T.; H. KUROKAWA, N. SHIBATA, et al.: A preliminary survey of extended-spectrum b -lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol. Lett. 184: 53 56, ) Jpn. J. Antibiotics 53: , ) ,180 Jpn. J. Antibiotics 53: , ) P. aeruginosa Acinetobacter spp. 75(8): , ) SAITO, A.; T. INAMATSU, J. OKADA, et al.: Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released. J. Infect. Chemother. 5: , 1999

33 102(102) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 29) KANAZAWA, K.; K. NOUDA, M. SUNAGAWA: Structure-activity relationships of carbapenem compounds to anti- Haemophilus influenzae activity and affinity for penicillin-binding proteins: Effect of 1-methyl group and C-2 side chain. J. Antibiotics 50: , ) TANAKA, M.; H. NAKAYAMA, H. TUNOE, et al.: A remarkable reduction in the susceptibility of Neisseria gonorrhoeae isolates to cephems and the selection of antibiotic regimens for the single-dose treatment of gonococcal infection in Japan. J. Infect. Chemother. 8: 81 86, ) 45: , ) BANDOH, K.; K. UENO, K. WATANABE, et al.: Susceptibility patterns and resistance to imipenem in Bacteroides fragilis group species in Japan. Clin. Infect. Dis. 16 (Suppl. 4): S382 S386, 1993 NATIONWIDE SURVEILLANCE OF PARENTERAL ANTIBIOTICS CONTAINING MEROPENEM ACTIVITIES AGAINST CLINICALLY ISOLATED STRAINS IN 2002 KEIZO YAMAGUCHI Department of Microbiology, Toho University School of Medicine YOSHIKAZU ISHII and MORIHIRO IWATA* Department of Microbiology, Toho University School of Medicine *Department of Laboratory Medicine, Toho University Omori Hospital NAOKI WATANABE and NOBUYUKI UEHARA Department of Clinical Laboratory Medicine, Division of Laboratory Diagnosis, Sapporo Medical University School of Medicine HIROSHI YOSHIDA and TOSHIO SATOH Department of Clinical Laboratory Medicine and Clinical Laboratories, Fukushima Medical University MASAMI MURAKAMI and AYAKO TAKAHASHI* Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine *Clinical Laboratory Center, Gunma University Hospital MINORU YASUJIMA and TAKESHI KASAI Department of Laboratory Medicine, Hirosaki University, School of Medicine AKIRA SUWABE and RITSUKO OBATA* Department of Laboratory Medicine, Iwate Medical University School of Medicine *Department of Central Clinical Laboratories, Iwate Medical University School of Medicine MITSUO KAKU and KEIJI KANEMITSU Division of Molecular Diagnostics, Tohoku University Graduate School of Medicine KOUICHI ITOH and YASUHIRO SHIBUYA Clinical Laboratory Medicine, Jichi Medical School HARUSHIGE KANNO and SETSUKO KUBO Clinical Laboratory, Chiba University Hospital SHIGEFUMI MAESAKI and GIICHI HASHIKITA* Department of Infectious Disease & Infection Control, Saitama Medical School *Department of Laboratory Medicine, Saitama Medical School

34 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS (103) JUN IGARI and TOYOKO OGURI* Department of Clinical Pathology, Juntendo University School of Medicine *Department of Clinical Laboratories, Juntendo University Hospital MASANORI AIHARA Department of Clinical Pathology, Tenri Hospital SHOHIRO KINOSHITA Clinical Laboratory, Kobe University Hospital JUN OKADA and YOKO TAZAWA Clinical Laboratory, Kanto Medical Center, NTT EC HIDEKI NAKASHIMA and HIROMU TAKEMURA Department of Microbiology, St. Marianna University School of Medicine TOSHINOBU HORII Department of Laboratory Medicine, Hamamatsu University School of Medicine HISASHI BABA Department of Infectious Diseases, Nagoya University School of Medicine SHIOMI ISHIGO Clinical Laboratory, Ogaki Municipal Hospital TOMOHIKO TAMINATO and KIYOSHI NEGAYAMA Department of Laboratory Medicine, Kagawa Medical University MITSUHARU MURASE and HITOSHI MIYAMOTO Clinical Laboratory, Ehime University Hospital NOBUCHIKA KUSANO and EIICHIROU MIHARA Department of Laboratory Medicine, Okayama University Graduate School of Medicine and Dentistry MASAYUKI KAMBE and HIDEYUKI ITAHA Department of Clinical Laboratory Medicine, Hiroshima University, Faculty of Medicine NAOHISA FUJITA and TOSHIAKI KOMORI Department of Clinical and Laboratory Medicine, Kyoto Prefectural University of Medicine JUNKO ONO and HISAE YOSHIMURA Central Clinical Laboratory, Fukuoka University Hospital SATOSHI ICHIYAMA and SHIGETAKA MAEDA Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine YOICHI HIRAKATA and JUNICHI MATSUDA Department of Laboratory Medicine, Nagasaki University School of Medicine KIYOHARU YAMANAKA and YOKO MURATA Division of Clinical Laboratory, Ohtemae Hospital TETSUNORI SAIKAWA and KAZUFUMI HIRAMATSU Clinical Laboratory Center, Oita Medical University Hospital The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 899 strains of Gram-positive bacteria, 1500 strains of Gram-negative bacteria, and 158 strains of anaerobic

35 104(104) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. bacteria obtained from 28 medical institutions during 2002 was measured. The results were as follows; 1. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MIC 90 of MEPM against Pseudomonas aeruginosa was the lowest of the drugs tested. MEPM showed low cross-resistant rate against both imipenem-resistant P. aeruginosa and ciprofloxacin-resistant P. aeruginosa. MEPM was active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE). 2. The proportion of extended-spectrum b -lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli and 1.9% (2 strains) in Klebsiella pneumoniae. Carbapenems including MEPM were active against these ESBL strains. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 7 years after available for commercial use.

日本化学療法学会雑誌第64巻第4号

日本化学療法学会雑誌第64巻第4号 β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.

More information

日本化学療法学会雑誌第61巻第6号

日本化学療法学会雑誌第61巻第6号 β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae

More information

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)

More information

03-b-„FŒ{›xŒ¾-4.02

03-b-„FŒ{›xŒ¾-4.02 518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus

More information

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,

More information

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus

More information

02-(a)-Łi’ì™·Łv-4.11

02-(a)-Łi’ì™·Łv-4.11 THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus

More information

R06_01

R06_01 Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2

More information

Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against

More information

2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.

2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N. Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin

More information

Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains

More information

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas

More information

Table 1. Antimicrobial drugs using for MIC

Table 1. Antimicrobial drugs using for MIC Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive

More information

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus

More information

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium

More information

Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz

Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime

More information

CHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),

More information

Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 1

Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 1 Dec. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 46 431 ( 45 ) 2006 1) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 16) 16) 17) 17) 1) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10)

More information

1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus

More information

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table

More information

CHEMO THE RAPY OCT. 1994

CHEMO THE RAPY OCT. 1994 bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis

More information

172( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 2 Apr. 2002 1 19 6 2002 5 8 4 254 254 (PBP) 90 83 65 142 PBP pbp1a, pbp2x, pbp2b 121 (49%), pbp1a, pbp2x 30 (12%), pbp2x, pbp2b 16 (6%), pbp2x 61 (24%),

More information

PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin

PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin Key words : Clinical isolates, Antibacterial susceptibility, Scale of hospital PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC=

More information

DIC vegetation 1 nonbacterial thrombogenic e

DIC vegetation 1 nonbacterial thrombogenic e 2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus

More information

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69

More information

Fig.1 Chemical structure of BAY o 9867

Fig.1 Chemical structure of BAY o 9867 Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985

More information

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.); VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical

More information

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter

More information

Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil

More information

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine

More information

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella

More information

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof 242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF

More information

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,

More information

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -

366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli - Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486

More information

R01

R01 1. 集計対象医療機関数 (1,792 医療機関 ) 13.2% (7 医療機関 ) 900 床以上 N=53 86.8% (46 医療機関 ) 19.2% (70 医療機関 ) 500 899 床 N=365 80.8% (295 医療機関 ) JANIS 参加 * 200 499 床 N=2,231 43.4% (968 医療機関 ) 56.6% (1,263 医療機関 ) JANIS 参加 200

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS ( 79)

THE JAPANESE JOURNAL OF ANTIBIOTICS ( 79) 346 ( 78) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 2007 72 12,919 NTT THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 347 ( 79) 348 ( 80) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 THE JAPANESE JOURNAL OF

More information

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,

More information

VOL. 43 NO. 4

VOL. 43 NO. 4 VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY

More information

Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,

More information

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus

More information

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia

More information

Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 11( 11 ) 2003 12 17 (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I. 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3 1997 1) (1985)

More information

(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia

(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor

More information

04-c-„FŒ{›xŒ¾-4.01

04-c-„FŒ{›xŒ¾-4.01 544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 2. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 545( 57 ) 9 5 2003 8 2004 714 565 719 50 20 39 0 9 70 79 44.4 91.7% Escherichia coli

More information

Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates

More information

日本化学療法学会雑誌第53巻第S-1号

日本化学療法学会雑誌第53巻第S-1号 Doripenem in vitro Doripenem in vitro 7 7 3 DRPM in vitro DRPM 00 DRPM Staphylococcus Streptococcus µ gml MIC90 Moraxella catarrhalishaemophilus influenzae µ gml MIC90 imipenem IPM panipenem meropenemmepm

More information

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,

More information

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,

More information

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative

More information

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331

More information

Fig. 1 Chemical structure of DL-8280

Fig. 1 Chemical structure of DL-8280 Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.

More information

日本化学療法学会雑誌第51巻第4号

日本化学療法学会雑誌第51巻第4号 000 000 0 000 0 Methicillin resistant Staphylococcus aureusmrsa.methicillin resistant S. epidermidismrse.0 MRSA MRSE arbekacinabkquinupristindalfopristinqprdpr vancomycin MIC0. ml Streptococcus pneumoniae

More information

Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA

Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA Aug. 2009 THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 277 (9) 2007 NTT JA 278 (10) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug. 2009 2009 4 10 1982 7 2007 2007 4 2008 3 1 229 181 (79.0%) 683 24 395 288

More information

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration

More information

Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.

More information

概要 (2006 年 1 2 3 月分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動 向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 2005 年 2006 年 10~12

More information

日本化学療法学会雑誌第53巻第S-3号

日本化学療法学会雑誌第53巻第S-3号 moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium

More information

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 NTT

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 NTT June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 181 27 201072 12,866 JA 182 28 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 NTT June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 183 29 2012 3

More information

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin

More information

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of

More information

CHEMOTHERAPY

CHEMOTHERAPY CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity

More information

49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC lin (ABPC), e

49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC lin (ABPC), e Key words: MIC, agar dilution method, fastidious bacteria, Etes(R) 49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC

More information

CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative

More information

Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) 2008 NTT

Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) 2008 NTT Apr. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 12 105 ( 13 ) 2008 NTT 106 ( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr. 2010 JA 2010 1 27 1982 7 2008 2008 4 2009 3 1 215 173 (80.5%) 694 18 357

More information

1272 CHEMOTHERAPY MAR. 1975

1272 CHEMOTHERAPY MAR. 1975 1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides

More information

概要 (2004 年分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 ( ) 内は施設数 2002 年 2003 年 2004

More information

Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Assoc

Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Assoc J Infect Chemother (2012) 18:609 620 DOI 10.1007/s10156-012-0434-3 SURVEILLANCE Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of

More information

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega 1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity

More information

公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 Citrobacter koseri Proteus mirabilis Proteus vulgaris Serratia marcescens Pseudomonas aerugino

公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 Citrobacter koseri Proteus mirabilis Proteus vulgaris Serratia marcescens Pseudomonas aerugino 公開情報 2016 年 1 月 ~12 月年報 ( 全集計対象医療機関 ) 院内感染対策サーベイランス検査部門 検査部門におけるサーベイランスの概要と目的 本サーベイランスの目的は 細菌検査により検出される主要な細菌の分離頻度とその抗菌薬感受性を継続的に収集 解析し 医療機関における主要な細菌ならびに薬剤耐性菌の分離状況を明らかにすることである サーベイランスの対象となる主要菌ならびに薬剤耐性菌の分離率は

More information

スライド タイトルなし

スライド タイトルなし 第 4 回ひびき臨床微生物シンポジュウム June 24,27, 港ハウス 感受性検査を読む ( 同定検査結果確認やスクリーニング検査と捉えて ) ( 株 ) キューリン小林とも子 キューリン微生物検査課 塗抹鏡検グラム染色 分離培養検査血液 BTB, エッグーヨーク 報告書作成結果承認 同定検査 VITEK TSI,LIM クリスタル NF 薬剤感受性検査 MIC2 ディスク法 薬剤感受性結果 (

More information

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak

More information

日本化学療法学会雑誌第58巻第4号

日本化学療法学会雑誌第58巻第4号 Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p

More information

VOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus

More information

b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates

More information

CHEMOTHERAPY

CHEMOTHERAPY VOL.40 S-1 coagulase negative Staphylococcus sp, methicillin- resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter

More information

Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and

More information

CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table

More information

2.7 臨床概要

2.7 臨床概要 2.7 臨床概要 A/G Al-P ALT AST AT- AUC AZM BIPM BP BUN CEZ CFPN-PI CFU CLcr Cmax CNS COPD CPFX CRP CS CYP CVA DBT DHP-I DIC DRPM DRPM-DC FAS γ-gtp GCP GNB GNF-GNR GPB HAM - Staphylococcus C P450 -I Full Analysis

More information

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus

More information

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC, E. coli NIHJ JC-2 pneumoniae E. coli 106, K. pneumoniae

More information

43 Acontum apoiense 17 19581147 1988 17 2001 A4 A4 H17. 4.20. 3. 1012 131421 IT 50 10,340 11,521 2 3 8 9 9 10 10 15 19 20 21 21 1617 22 23 1904 1928 1940 Nature MRSA MRCNS VREVRSA PRSP BRNAR MDRP ESBL)MBL

More information

988 CHEMOTHERAPY NOV. 1971

988 CHEMOTHERAPY NOV. 1971 988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical

More information

CHEMOTHERAPY JUNE 1986

CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml

More information

VOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3

More information

Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic

More information

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS ,4 2,4 2,4 2,3,4 2,3,4 2,3, ,3, Garenoxacin GRNX Levofloxacin LV

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS ,4 2,4 2,4 2,3,4 2,3,4 2,3, ,3, Garenoxacin GRNX Levofloxacin LV Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 27 27 1,4 2,4 2,4 2,3,4 2,3,4 2,3,4 2 1 2,3,4 1 2 3 4 2015 10 21 9 Garenoxacin GRNX Levofloxacin LVFX Sitafloxacin STFX Moxifloxacin MFLX Pharmacokinetics-Pharmacodynamics

More information

Microsoft PowerPoint .片山(HP用修正).pptx

Microsoft PowerPoint .片山(HP用修正).pptx 平成 29 年度 第 1 回三重県感染対策 援ネットワーク研修会 2017/07/09 ( 臨床第 2 講義室 ) 講演 2 アンチバイオグラムの活 アンチバイオグラム作り 使い 独 政法 地域医療機能推進機構 四 市 津医療センター 薬剤科 副薬剤科 歳也 Japan Community Health care Organization (JCHO) Yokkaichi Hazu Medical

More information

MIC MIC...

MIC MIC... 50 mg 10% 2.7.36 2.7.36 2.7.36... 1 1.6... 1 2.6... 3 3.6... 5 3.16... 5 3.26... 12 3.36... 16 4.6... 17 5.6... 19 6.6... 20 2.7.3.3.16-1 MIC... 9 2.7.3.3.16-2 MIC... 10 2.7.3.3.16-3 MIC E. coli... 11

More information

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.

More information

untitled

untitled Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium

More information

CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur

CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur CHEMOTHERAPY NOV. 1985 Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aureus Streptococcus pyogenes Escherichia coli Klebsiella

More information

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC

400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17

More information

01-a-”Oı€™JŠY-4.02

01-a-”Oı€™JŠY-4.02 Apr. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 105( 1 ) Fosfomycin b- 2004 11 24 fosfomycin (FOM) FOM b- (cefazolin (CEZ), cefotiam (CTM), cefmetazole (CMZ) piperacillin (PIPC)) b - AmpC b- FOM glucose-6-phosphate

More information